Anti-CD40 monoclonal antibody

References

• Paulie S, Ehlin-Henriksson B, Mellstedt H, Koho H, Ben-Aissa H, Perlmann P. A p50 surface antigen restricted to human urinary bladder carcinomas and B lymphocytes. Cancer Immunol Immunother 1985;20 (1):23–28.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40 - CD40 ligand. J Leukoc Biol 2000;67 (1):2–17.
   PubMed Web of Science ®Google Scholar
• Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111–135.
   PubMed Web of Science ®Google Scholar
• Funakoshi S, Longo DL, Beckwith M, Conley DK, Tsarfaty G, Tsarfaty I et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83(10):2787–2794.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Treon SP, Hideshima T, Tai Y-T, Akiyama M, Richardson P et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003;121 (4):592–596.
   PubMed Web of Science ®Google Scholar
• Young LS, Eliopoulos AG, Gallagher NJ, Dawson CW. CD40 and epithelial cells: across the great divide. Immunol Today 1998;19(11):502–506.
   PubMedGoogle Scholar
• Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL et al. Role for CD40 - CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000;37(9):515–526.
   PubMed Web of Science ®Google Scholar
• Wingett DG, Vestal RE, Forcier K, Hadjokas N, Nielson CP. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res Treat 1998;50(1):27–36.
   Google Scholar
• Sabel MS, Yamada M, Kawaguchi Y, Chen FA, Takita H, Bankert RB. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol Immun-other 2000;49 (2):101–108.
   PubMed Web of Science ®Google Scholar
• Gallagher NJ, Eliopoulos AG, Agathangelo A, Oates J, Crocker J, Young LS. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol Pathol 2002;55 (2):110–120.
   PubMedGoogle Scholar
• Cooke PW, James ND, Ganesan R, Wallace M, Burton A, Young LS. CD40 expression in bladder cancer. J Pathol 1999;188(1):38–43.
   PubMed Web of Science ®Google Scholar
• Thomas WD, Smith MJ, Si Z, Hersey P. Expression of the co-stimulatory molecule CD40 on melanoma cells. hit J Cancer 1996;68(6):795–801.
   PubMed Web of Science ®Google Scholar
• Biancone L, Cantaluppi V, Camussi G. CD40 - CD154 interaction in experimental and human disease (review). hit J Mol Med 1999;3 (4):343–353.
   Google Scholar
• von Leoprechting A, van der Bruggen P, Pahl HL, Aruffo A, Simon JC. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 1999;59(6):1287–1294.
   PubMed Web of Science ®Google Scholar
• Stamenkovic I, Clark EA, Seed B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. Embo J 1989;8(5):1403–1410.
   Google Scholar
• Karpusas M, Hsu YM, Wang JH, Thompson J, Lederman S, Chess L et al. A crystal structure of an extracellular fragment of human CD40 ligand. Structure 1995;3(12):1426.
   PubMed Web of Science ®Google Scholar
• Yellin MJ, Lee JJ, Chess L, Lederman S. A human CD4- T cell leukemia subclone with contact-dependent helper func-rion. J Immunol 1991;147 (10):3389–3395.
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4 + T cells that induces contact-dependent B cell differentiation (help). J Exp Med 1992;175(4):1091–1101.
   PubMed Web of Science ®Google Scholar
• Armitage RJ, Sato TA, Macduff BM, Clifford KN, Alpert AR, Smith CA et al. Identification of a source of biologically active CD40 ligand. Eur J Immunol 1992;22(8):2071–2076.
   PubMed Web of Science ®Google Scholar
• Gauchat JF, Henchoz S, Fattah D, Mazzei G, Aubry JP, Jomotte T et al. CD40 ligand is functionally expressed on human eosinophils. Eur J Immunol 1995;25(3):863–865.
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391 (6667):591–594.
   PubMed Web of Science ®Google Scholar
• Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993;365(6444):340–343.
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin MJ, Inghirami G, Lee JJ, Knowles DM, Chess L. Molecular interactions mediating T-B lymphocyte collaboration in human lymphoid follicles. Roles of T cell- B-cell-activating molecule (5c8 antigen) and CD40 in contact-dependent help. J Immunol 1992;149(12):3817–3826.
   Google Scholar
• Hollenbaugh D, Grosmaire LS, Kullas CD, Chalupny NJ, Braesch-Andersen S, Noelle RJ et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. Embo J 1992;11 (12) :4313–4321.
   PubMed Web of Science ®Google Scholar
• Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA et al. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992;176(6):1543–1550.
   PubMed Web of Science ®Google Scholar
• Villa A, Notarangelo LD, Di Santo JP, Macchi PP, Strina D, Frattini A et al. Organization of the human CD4OL gene: implications for molecular defects in X chromosome-linked hyper-IgM syndrome and prenatal diagnosis. Proc Natl Acad Sci USA 1994;91 (6):2110–2114.
   PubMed Web of Science ®Google Scholar
• Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995;25 (6):1749–1754.
   Google Scholar
• Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A et al. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem 1995;270(13):7025–7028.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA. Temporal association of CD40 antigen expres-sion with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 1990;76(12):2449–2456.
   PubMed Web of Science ®Google Scholar
• Yellin MJ, Sinning J, Covey LR, Sherman W, Lee JJ, Glickman-Nir E et al. T lymphocyte T cell -B cell-activating molecule/CD4O-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994;153(2):666–674.
   PubMed Web of Science ®Google Scholar
• Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993;177 (4):925–935.
   PubMed Web of Science ®Google Scholar
• Schattner EJ, Elkon KB, Yoo DH, Tumang J, Krammer PH, Crow MK et al. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med 1995;182(5):1557–1565.
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Cohn LE et al. T-BAM/CD4O-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. J Immunol 1994;152(5):2163–2171.
   PubMed Web of Science ®Google Scholar
• Cleary AM, Fortune SM, Yellin MJ, Chess L, Lederman S. Opposing roles of CD95 (Fas/APO-1) and CD40 in the death and rescue of human low density tonsillar B cells. J Immunol 1995;155(7):3329–3337.
   Google Scholar
• Tsubata T, Wu J, Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993;364(6438):645–648.
   Google Scholar
• Lederman S, Cleary AM, Yellin MJ, Frank DM, Karpusas M, Thomas DW et al. The central role of the CD40-ligand and CD40 pathway in T-lymphocyte-mediated differentiation of B lymphocytes. Curr Opin Hematol 1996;3 (1):77–86.
   PubMedGoogle Scholar
• Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand - receptor pair for thymus-dependent B-cell activation. Immunol Today 1992;13 (11):431–433.
   Google Scholar
• Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993;72(2):291–300.
   PubMed Web of Science ®Google Scholar
• Aruffo A, Hollenbaugh D, Wu LH, Ochs HD. The molecular basis of X-linked agammaglobulinemia, hyper-IgM syndrome, and severe combined immunodeficiency in humans. Curr Opin Hematol 1994;1 (1):12–18.
   PubMedGoogle Scholar
• Caux C, Massacrier C, Vanberyliet B, Dubois B, Van Kooten C, Durand I et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994;180(4):1263–1272.
   PubMed Web of Science ®Google Scholar
• Peng X, Remade JE, Kasran A, Huylebroeck D, Ceuppens JL. IL-12 up-regulates CD40 ligand (CD154) expression on human T cells. J Immunol 1998;160(3):1166–1172.
   Google Scholar
• Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4 + T-helper and a T-killer cell. Nature 1998;393 (6684):474–478.
   PubMed Web of Science ®Google Scholar
• Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393(6684):478–480.
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van der Voort El, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40 - CD4OL interactions. Nature 1998;393(6684): 480–483.
   Google Scholar
• Arch RH, Gedrich RW, Thompson CB. Tumor necrosis factor receptor-associated factors (TRAFs) - a family of adapter proteins that regulates life and death. Genes Dev 1998;12(18):2821–2830.
   Google Scholar
• Pullen SS, Dang TT, Crate JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of down-stream pathways by distinct TRAFs. J Biol Chem 1999;274(20):14246–14254.
   Google Scholar
• Ren CL, Mono T, Fu SM, Geha RS. Signal transduction via CD40 involves activation of lyn kinase and phosphatidylino-sito1-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med 1994;179(2):673–680.
   PubMed Web of Science ®Google Scholar
• Ren CL, Fu SM, Geha RS. Protein tyrosine kinase activation and protein kinase C translocation are functional components of CD40 signal transduction in resting human B cells. Immunol Invest 1994;23(6–7):437-448.
   Google Scholar
• Davies CC, Mason J, Wakelam MJ, Young LS, Eliopoulos AG. Inhibition of phosphatidylinositol 3-kinase- and ERK MAPK-regulated protein synthesis reveals the pro-apoptotic properties of CD40 ligation in carcinoma cells. J Biol Chem 2004;279 (2):1010–1019.
   Google Scholar
• Tsukamoto N, Kobayashi N, Azuma S, Yamamoto T, Inoue J. Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40. Proc Natl Acad Sci USA 1999;96(4):1234–1239.
   Google Scholar
• Young LS, Dawson CW, Brown KW, Rickinson AB. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer 1989;43(5):786–794.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. Functional role of CD40 and its ligand. Int Arch Allergy Immunol 1997;113(4):393–399.
   PubMed Web of Science ®Google Scholar
• Singh SR, Casper K, Summers S, Swerlick RA. CD40 expression and function on human dermal microvascular endothelial cells: role in cutaneous inflammation. Chin Exp Dermatol 2001;26(5):434–440.
   PubMed Web of Science ®Google Scholar
• Gormand F, Briere F, Peyrol S, Raccurt M, Durand I, Ait-Yahia S et al. CD40 expression by human bronchial epithelial cells. Scand J Immunol 1999;49(4):355–361.
   PubMed Web of Science ®Google Scholar
• Yellin MJ, D'Agati V, Parkinson G, Han AS, Szema A, Baum D et al. Immunohistologic analysis of renal CD40 and CD4OL expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997;40(1):124–134.
   Google Scholar
• Galy AH, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol 1992;149(3):775–782.
   PubMed Web of Science ®Google Scholar
• Iwata M, Soya K, Sawa M, Sakimoto T, Hwang DG. CD40 expression in normal human cornea and regulation of CD40 in cultured human corneal epithelial and stromal cells. Invest Ophthalmol Vis Sci 2002;43(2):348–357.
   Google Scholar
• Agathanggelou A, Niedobitek G, Chen R, Nicholls J, Yin W, Young LS. Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am J Pathol 1995;147(4):1152–1160.
   Google Scholar
• Hess S, Engelmann H. A novel function of CD40: induction of cell death in transformed cells. J Exp Med 1996;183(1):159–167.
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMPl: involvement of TRAF3 as a common mediator. Oncogene 1996;13 (10): 2243–2254.
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000;20(15):5503–5515.
   PubMed Web of Science ®Google Scholar
• Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC et al. Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: induction of bax. Blood 2002;100 (1): 217–223.
   PubMed Web of Science ®Google Scholar
• Hirano A, Longo DL, Taub DD, Ferris DK, Young LS, Eliopoulos AG et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999;93 (9):2999–3007.
   PubMed Web of Science ®Google Scholar
• Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J et al. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst 2002;94 (18) :1381–1395.
   PubMed Web of Science ®Google Scholar
• Tong AW, Papayoti MH, Netto G, Armstrong DT, Ordonez G, Lawson JM et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Chin Cancer Res 2001;7(3):691–703.
   Web of Science ®Google Scholar
• Ghamande S, Hylander BL, Oflazoglu E, Lele S, Fanslow W, Repasky EA. Recombinant CD40 ligand therapy has signifi-cant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001;61(20):7556–7562.
   PubMed Web of Science ®Google Scholar
• Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER, Norris CM Jr. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Chin Cancer Res 1999;5(8):2261–2270.
   Google Scholar
• Marches R, Racila E, Tucker TF, Picker L, Mongini P, Hsueh R et al. Tumour dormancy and cell signalling - III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. Ther Immunol 1995;2(3):125–136.
   PubMedGoogle Scholar
• Reff ME, Garner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83(2):435–445.
   PubMed Web of Science ®Google Scholar
• Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91(5):1644–1652.
   Google Scholar
• Cragg MS, Morgan SM, Chan FIT, Morgan BP, Filatov AV, Johnson PW et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101(3):1045–1052.
   PubMed Web of Science ®Google Scholar
• Heit W, Bunjes D, Wiesneth M, Schmeiser T, Arnold R, Hale Get al. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow trans-plantation. Br J Haematol 1986;64(3):479–486.
   Google Scholar
• Dyer MJ, Hale G, Hayhoe FG, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989;73(6):1431–1439.
   PubMed Web of Science ®Google Scholar
• Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23(5):1098–1104.
   Google Scholar
• Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(4 Suppl. 12):60–70.
   Google Scholar
• Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002;9(2):75–85.
   PubMed Web of Science ®Google Scholar
• Eliopoulos AG, Young LS. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004;4(4):360–367.
   PubMed Web of Science ®Google Scholar
• French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5(5):548–553.
   PubMed Web of Science ®Google Scholar
• Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG et al. CD40 ligation for immunotherapy of solid tumours. J Immunol Meth 2001;248(1-2):139–147.
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003;102(4):1449–1457.
   PubMed Web of Science ®Google Scholar
• Early GS, Zhao W, Burns CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157 (7): 3159 — 3164.
   Google Scholar
• Kitagawa M, Suzuki H, Adachi Y, Nakamura H, Yoshino S, Sumida T. Interferon-gamma enhances interleukin 12 pro-duction in rheumatoid synovial cells via CD40 — CD154 dependent and independent pathways. J Rheumatol 2001;28(8):1764— 1771.
   PubMed Web of Science ®Google Scholar
• Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO et al. CD40 ligand— CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997;159(9):4620 — 4627.
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998;137 (Suppl.): S89 — S95.
   Google Scholar
• Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394(6689):200 —203.
   Google Scholar
• Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M et al. Expression of stromelysin-3 in athero-sclerotic lesions: regulation via CD40 — CD40 ligand signaling in vitro and in vivo. J Exp Med 1999;189(5):843–853.
   PubMed Web of Science ®Google Scholar
• Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5(11):1313 — 1316.
   PubMed Web of Science ®Google Scholar
• Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ et al. CD40 — CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996;93(6):2499 — 2504.
   PubMed Web of Science ®Google Scholar
• Tan J, Town T, Suo Z, Wu Y, Song S, Kundtz A et al. Induction of CD40 on human endothelial cells by Alzheimer's beta-amyloid peptides. Brain Res Bull 1999;50(2):143 — 148.
   PubMed Web of Science ®Google Scholar
• Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F et al. Microglial activation resulting from CD40 — CD4OL interac-tion after beta-amyloid stimulation. Science 1999;286(5448): 2352 —2355.
   PubMed Web of Science ®Google Scholar
• Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A et al. CD40 — gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40 — gp39 pathway. Trans-plantation 1996;61 (1):4 — 9.
   Google Scholar
• Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Berning JD, Buchanan K et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejec-tion in nonhuman primates. Nat Med 1999;5(6):686— 693.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Dutcher JP, Anderson JE, Eckhardt SG, Stephans KF, Razvillas B et al. Phase I study of recombinant human CD40 ligand in cancer patients. J Chin Oncol 2001;19(13):3280–3287.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Cantwell MJ, Woods SJ, Rassenti LZ, Prussak CE, Kipps TJ. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000;96(9):2917 — 2924.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Yotnda P, Rousseau RE, Mei Z, Smith S, Rill D et al. Transgenic expression of CD4OL and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001;8(5):378— 387.
   PubMed Web of Science ®Google Scholar